Learning versus confirming in clinical drug development

Clinical Pharmacology & Therapeutics (1997) 61, 275–291; doi:

[1]  E. Vonesh,et al.  Mixed-effects nonlinear regression for unbalanced repeated measures. , 1992, Biometrics.

[2]  D. Rubin,et al.  Intention‐to‐treat analysis and the goals of clinical trials , 1995, Clinical pharmacology and therapeutics.

[3]  B. Chabner,et al.  Pharmacologically guided phase I clinical trials based upon preclinical drug development. , 1990, Journal of the National Cancer Institute.

[4]  J B Greenhouse,et al.  Bayesian methods for phase I clinical trials. , 1992, Statistics in medicine.

[5]  L B Sheiner,et al.  The intellectual health of clinical drug evaluation , 1991, Clinical pharmacology and therapeutics.

[6]  R. O'neill.  Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization. , 1995, Statistics in medicine.

[7]  L B Sheiner,et al.  Time and Theophylline Concentration Help Explain the Recovery of Peak Flow Following Acute Airways Obstruction , 1993, Clinical pharmacokinetics.

[8]  D. Seitz,et al.  Trimetrexate: a critical appraisal of the phase II clinical trial experience: evidence of drug discovery-clinical development disjunction. , 1994, Cancer investigation.

[9]  D R Mould,et al.  Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam , 1995, Clinical pharmacology and therapeutics.

[10]  D A Berry,et al.  Experimental design for drug development: a Bayesian approach. , 1991, Journal of biopharmaceutical statistics.

[11]  Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development , 1992 .

[12]  C. Kelly,et al.  Monotone smoothing with application to dose-response curves and the assessment of synergism. , 1990, Biometrics.

[13]  J. Urquhart,et al.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans , 1987, Clinical pharmacology and therapeutics.

[14]  S L Shafer,et al.  Pharmacokinetic‐pharmacodynamic modeling in drug development: Application to the investigational opioid trefentanil , 1994, Clinical pharmacology and therapy.

[15]  L B Sheiner,et al.  A simulation study comparing designs for dose ranging. , 1991, Statistics in medicine.

[16]  W. Alves,et al.  Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. , 1996, Journal of neurosurgery.

[17]  Donald R. Stanski,et al.  Using the Electroencephalographic (EEG) Fingerprint to Define the Clinical Pharmacodynamics (PD) of A Novel Opioid: Application to Remifentanil (REMI) , 1996 .

[18]  T G Filloon.  Estimating the minimum therapeutically effective dose of a compound via regression modelling and percentile estimation. , 1995, Statistics in medicine.

[19]  Nicholas H. G. Holford,et al.  The Population Approach: Rationale, Methods, and Applications in Clinical Pharmacology and Drug Development , 1994 .

[20]  L. Sheiner.  Clinical pharmacology and the choice between theory and empiricism , 1989, Clinical pharmacology and therapeutics.

[21]  D J Spiegelhalter,et al.  Applying Bayesian ideas in drug development and clinical trials. , 1993, Statistics in medicine.

[22]  D B Rubin,et al.  Practical implications of modes of statistical inference for causal effects and the critical role of the assignment mechanism. , 1991, Biometrics.

[23]  C C Peck,et al.  The randomized concentration-controlled trial: an evaluation of its sample size efficiency. , 1991, Controlled clinical trials.

[24]  G. Box.  Use and Abuse of Regression , 1966 .

[25]  P. Ward,et al.  Effect of age and gender on tirilazad pharmacokinetics in humans , 1994, Clinical pharmacology and therapy.

[26]  R Couch,et al.  Theophylline Target Concentration in Severe Airways Obstruction — 10 or 20 mg/L? , 1993, Clinical pharmacokinetics.